Andere talen StemRIM

Aandelen

4599

JP3399690001

Vertraagde tijd Japan Exchange Andere beurzen 04:08:52 08-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
427 ^JPY	+1,43%		-0,47%	-26,12%

13/03	StemRIM kondigt de start aan van Fase 2 klinische studie voor Redasemtide in ischemische cardiomyopathie	CI
31/01	StemRIM Inc. kondigt patentregistratie (Rusland) aan voor het gebruik van het HMGB1-fragmentpeptide, als aanvullende therapeutische indicatie voor kraakbeenaandoeningen	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

StemRIM Files Australian Patent Application for Cardiomyopathy Treatment	18/06
StemRIM to Seek Shareholders' Approval on Capital Stock Reduction	09/05
StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy	13/03
StemRIM Inc. Announces Patent Registration for the Use of the HMGB1 Fragment Peptide, as an Additional Therapeutic Indication of Cartilage Disorders	31/01
StemRIM Allocates 300 Stock Options to R&D Partner	29/12
StemRIM to Issue Stock Acquisition Rights	14/12
StemRIM Issues Over 300 Million Yen of Shares as Restricted Stock Compensation	07/12
StemRIM Enters into Contract for Implementation of Phase 2 Investigator-Initiated Clinical Trial Targeting Ischemic Cardiomyopathy Using Redasemtide, in Collaboration with Osaka University Hospital and Shionogi & Co	04/12
StemRIM Issues 433,000 Shares as Restricted Stock Compensation	17/11
StemRIM, Shiseido, Osaka University Extend Skin Aging Research Collaboration	17/11
StemRIM Discloses Issuance Details of Stock Options to Directors	20-09-23
Stemrim Inc. Announces Patent Registration (Us) for the Use of the Hmgb1 Fragment Peptide, Redasemtide	06-09-23
StemRIM Announces Patent Registration for the Use of Redasemtide as an Additional Treatment for Cardiomyopathy and Old Myocardial Infarction	04-09-23
StemRIM Inc. Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide Targeting Acute Ischemic Stroke	31-07-23
StemRIM Inc. Announces Commencement of Global Late Phase 2 Clinical Trial for Redasemtide in Patients with Acute Ischemic Stroke in the Europe and China	25-07-23
StemRIM Inc. Announces Patent Registration for the Use of the Hmgb1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction	18-07-23
StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023	19-06-23
Shionogi & Co., Ltd. - Orphan Drug Designation for Redasemtide for Dystrophic Epidermolysis Bullosa	24-05-23
StemRIM Inc. Announces Publication of Scientific Articles for Stem Cell Gene Therapy	16-05-23
StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke	28-04-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen StemRIM

Aandelen

4599

JP3399690001

Andere talen

Filters